RecruitingNCT07064746

Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma

Studying Neuroblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nanjing First Hospital, Nanjing Medical University
Principal Investigator
Guoqiang Shao, Dr
Nanjing First Hospital, Nanjing Medical University
Intervention
¹²³I-MIBG SPECT/CT(diagnostic_test)
Enrollment
150 enrolled
Eligibility
18 years · All sexes
Timeline
2022 – 2027

Study locations (1)

Collaborators

Jiangsu Province Hospital of Traditional Chinese Medicine

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07064746 on ClinicalTrials.gov

Other trials for Neuroblastoma

Additional recruiting or active studies for the same condition.

See all trials for Neuroblastoma →

← Back to all trials